U.S. markets open in 9 hours 12 minutes

Aethlon Medical, Inc. (EJU.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.2150-0.0160 (-6.93%)
At close: 03:23PM CEST

Aethlon Medical, Inc.

11555 Sorrento Valley Road
Suite 203
San Diego, CA 92121
United States
619 941 0360

IndustryMedical Devices
Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Dr. Charles J. Fisher Jr., M.D.CEO, Director & Member of Extracorporeal Therapy Advisory Board460kN/A1947
Mr. Guy F. Cipriani BS (Eng.), MBASr. VP, Chief Bus. Officer & Director347.5kN/A1970
Dr. Steven P. LaRosa M.D.Chief Medical Officer430kN/A1967
Mr. James B. Frakes M.B.A.CFO, Sr. VP of Fin. & Sec.N/AN/A1957
Dr. Lee D. Arnold Ph.D.Chief Scientific OfficerN/AN/A1960
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.

Corporate Governance

Aethlon Medical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.